Shanghai Unicar-therapy Bio-medicine Technology Co.,ltd
Clinical trials sponsored by Shanghai Unicar-therapy Bio-medicine Technology Co.,ltd, explained in plain language.
-
Experimental CAR-T therapy trial for blood cancer withdrawn before starting
Disease control TerminatedThis study was designed to test a new type of CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The goal was to see if it was safe and effective, but the trial was wit…
Phase: PHASE1 • Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 08:16 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphoma
Disease control TerminatedThis study was designed to test a new treatment called CD30-targeted CAR-T cells for people with lymphoma that has returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that carry a pro…
Phase: PHASE1 • Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 08:08 UTC